Jing-Gen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing-Gen Liu has a total of 331 co-authors. Here are the top co-authors by number of shared publications:
Zhi-Qiang Chi
Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica and Collaborative Innovation Center for Brain Science, Chinese Academy of Science, Shanghai 201203, China
17 shared publicationsYu-Jun Wang
Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications- Yu-Jun Wang
CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications Jie Chen
13 shared publications- Wei Li
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Fudan University, No. 826 Zhangheng Road, Shanghai, 201203, China
11 shared publications - Chi Xu
Department of Neurobiology and Acupuncture Research, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China
10 shared publications
Latest Publications
- 22 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-13
Kappa opioid receptor-dependent depressive-like behaviors associated with morphine withdrawal contribute to stress-induced reinstatement of morphine seeking
Negative effects during withdrawal heighten vulnerability to relapse in clinical settings. However, preclinical evidence linking withdrawal-induced negative emotions to relapse vulnerability remains limited. Previously, we have demonstrated that kappa opioid receptor (KORs) activation in the amygdala and subsequent inhibition of the amygdala-to-nucleus accumbens circuit mediate morphine withdrawal-induced depressive-like behaviors. In this study, we established a positive correlation between withdrawal-induced depressive-like behavior and stress-induced reinstatement in male mice. We found that morphine-treated mice displaying higher conditioned place preference (CPP) scores also exhibited more severe depressive-like behaviors during withdrawal and subsequently showed more pronounced CPP reinstatement following forced swim stress (FSS). We further found that inhibition of KOR activation in the basolateral amygdala (BLA), or activation of the BLA-NAc circuit, attenuated withdrawal-induced depressive-like behaviors and prevented subsequent stress-induced CPP reinstatement. Conversely, overexpression of KORs in the BLA-NAc circuit exacerbated these phenotypes, while genetic ablation of KORs in this circuit provided protective effects against these behaviors. Moreover, we identified a specific population of prelimbic cortex prodynorphinergic (PrLPdyn) neurons projecting to the BLA that are activated during both morphine withdrawal and FSS. Inhibition of these BLA-projecting PrLPdyn neurons alleviated morphine withdrawal-induced depressive-like behaviors and blocked stress-induced CPP reinstatement. Collectively, these findings support the idea that negative affective states during opioid withdrawal may drive relapse vulnerability, and the dynorphin/KOR system represents a critical therapeutic target for reducing negative effects and preventing relapse.
- 22 September 2026
- Published by Springer Nature in Neuropsychopharmacology
- p. 1-13
Kappa opioid receptor-dependent depressive-like behaviors associated with morphine withdrawal contribute to stress-induced reinstatement of morphine seeking
Negative effects during withdrawal heighten vulnerability to relapse in clinical settings. However, preclinical evidence linking withdrawal-induced negative emotions to relapse vulnerability remains limited. Previously, we have demonstrated that kappa opioid receptor (KORs) activation in the amygdala and subsequent inhibition of the amygdala-to-nucleus accumbens circuit mediate morphine withdrawal-induced depressive-like behaviors. In this study, we established a positive correlation between withdrawal-induced depressive-like behavior and stress-induced reinstatement in male mice. We found that morphine-treated mice displaying higher conditioned place preference (CPP) scores also exhibited more severe depressive-like behaviors during withdrawal and subsequently showed more pronounced CPP reinstatement following forced swim stress (FSS). We further found that inhibition of KOR activation in the basolateral amygdala (BLA), or activation of the BLA-NAc circuit, attenuated withdrawal-induced depressive-like behaviors and prevented subsequent stress-induced CPP reinstatement. Conversely, overexpression of KORs in the BLA-NAc circuit exacerbated these phenotypes, while genetic ablation of KORs in this circuit provided protective effects against these behaviors. Moreover, we identified a specific population of prelimbic cortex prodynorphinergic (PrLPdyn) neurons projecting to the BLA that are activated during both morphine withdrawal and FSS. Inhibition of these BLA-projecting PrLPdyn neurons alleviated morphine withdrawal-induced depressive-like behaviors and blocked stress-induced CPP reinstatement. Collectively, these findings support the idea that negative affective states during opioid withdrawal may drive relapse vulnerability, and the dynorphin/KOR system represents a critical therapeutic target for reducing negative effects and preventing relapse.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Kappa opioids suppress histaminergic itch by inhibiting mediodorsal thalamus-projecting claustrum glutamatergic neurons
Itch, an uncomfortable sensation that induces scratching, is suppressed by activation of kappa opioid receptors (KORs). KOR agonists, such as Nalfurafine, offer potent central antipruritic effects, yet the underlying mechanisms are not fully understood. In this study, we report the important role of glutamatergic neurons in the claustrum (CLA) in itch modulation. Chemogenetic inhibition of these neurons significantly reduces histamine-induced scratching behavior, whereas their activation heightens scratching behavior. These CLA Glu neurons connect to the mediodorsal thalamus (MD), forming a pathway that modulates itch sensations. Optogenetic manipulation of the CLA Glu -MD pathway demonstrates that its inhibition decreases scratching behavior, whereas activation increases it. Notably, CLA Glu neurons highly express KORs, and treatment with Nalfurafine markedly inhibits histamine-induced CLA Glu neuronal activation. Conditional knockdown of KORs in CLA Glu neurons or the CLA Glu -MD circuit diminishes Nalfurafine’s antipruritic effects. These findings provide insight into the neural circuits involved in histaminergic itch and the action of KOR agonists.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Kappa opioids suppress histaminergic itch by inhibiting mediodorsal thalamus-projecting claustrum glutamatergic neurons
Itch, an uncomfortable sensation that induces scratching, is suppressed by activation of kappa opioid receptors (KORs). KOR agonists, such as Nalfurafine, offer potent central antipruritic effects, yet the underlying mechanisms are not fully understood. In this study, we report the important role of glutamatergic neurons in the claustrum (CLA) in itch modulation. Chemogenetic inhibition of these neurons significantly reduces histamine-induced scratching behavior, whereas their activation heightens scratching behavior. These CLA Glu neurons connect to the mediodorsal thalamus (MD), forming a pathway that modulates itch sensations. Optogenetic manipulation of the CLA Glu -MD pathway demonstrates that its inhibition decreases scratching behavior, whereas activation increases it. Notably, CLA Glu neurons highly express KORs, and treatment with Nalfurafine markedly inhibits histamine-induced CLA Glu neuronal activation. Conditional knockdown of KORs in CLA Glu neurons or the CLA Glu -MD circuit diminishes Nalfurafine’s antipruritic effects. These findings provide insight into the neural circuits involved in histaminergic itch and the action of KOR agonists.
- 26 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 180, 116727
Eleutheroside B alleviates LPS-induced depressive-like behaviors by suppressing the TLR4/MyD88/NF-κB signaling pathway in the dentate gyrus
- 26 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 180, 116727
Eleutheroside B alleviates LPS-induced depressive-like behaviors by suppressing the TLR4/MyD88/NF-κB signaling pathway in the dentate gyrus
- 5 February 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 806, 153411
SLL-023ACP, a KOR/MOR dual agonist, produces potent antinociception with fewer side effects
- 5 February 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 806, 153411
SLL-023ACP, a KOR/MOR dual agonist, produces potent antinociception with fewer side effects
- 24 December 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (6) , 2991-3009
Astroglial kappa opioid receptor-mediated reduction of glutamate exchanger xCT in the prelimbic cortex underlies chronic stress-induced depressive-like behaviors
Multiple lines of evidence, including clinical and preclinical, associate depression with dysregulated glutamate homeostasis in the central nervous system. The astrocyte-enriched cysteine/glutamate antiporter, xCT, plays a pivotal role in maintaining this homeostasis, and its dysfunction is linked to depressive-like behaviors induced by chronic stress. However, the exact mechanism through which chronic stress results in xCT dysfunction remains poorly understood. In this study, we demonstrate that chronic social defeat stress (CSDS) downregulates xCT expression in the prelimbic cortex (PL), a key cortical region involved in the aetiology of depression, through astroglial kappa opioid receptor (KOR)-dependent, p38 MAPK-mediated upregulation of miR-3084-5p expression, which in turn downregulates xCT expression by inhibiting mRNA that encodes xCT. Knockdown of KORs as well as overexpression of xCT in the PL astrocytes significantly attenuates CSDS-induced depressive-like behaviors. Blockade of p38 MAPK activity or suppression of miR-3084-5p function restores xCT expression and alleviates depressive-like behaviors. Together, this study reveals a novel mechanism by which chronic stress deregulates glutamate homeostasis and consequently results in depression.
- 24 December 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (6) , 2991-3009
Astroglial kappa opioid receptor-mediated reduction of glutamate exchanger xCT in the prelimbic cortex underlies chronic stress-induced depressive-like behaviors
Multiple lines of evidence, including clinical and preclinical, associate depression with dysregulated glutamate homeostasis in the central nervous system. The astrocyte-enriched cysteine/glutamate antiporter, xCT, plays a pivotal role in maintaining this homeostasis, and its dysfunction is linked to depressive-like behaviors induced by chronic stress. However, the exact mechanism through which chronic stress results in xCT dysfunction remains poorly understood. In this study, we demonstrate that chronic social defeat stress (CSDS) downregulates xCT expression in the prelimbic cortex (PL), a key cortical region involved in the aetiology of depression, through astroglial kappa opioid receptor (KOR)-dependent, p38 MAPK-mediated upregulation of miR-3084-5p expression, which in turn downregulates xCT expression by inhibiting mRNA that encodes xCT. Knockdown of KORs as well as overexpression of xCT in the PL astrocytes significantly attenuates CSDS-induced depressive-like behaviors. Blockade of p38 MAPK activity or suppression of miR-3084-5p function restores xCT expression and alleviates depressive-like behaviors. Together, this study reveals a novel mechanism by which chronic stress deregulates glutamate homeostasis and consequently results in depression.
- 12 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110765
Identification and validation of Slit3 as a depression biomarker modulating dynorphinergic neurons in the hypothalamic paraventricular nucleus
- 12 November 2025
- Published by Elsevier in Neuropharmacology
- Vol. 283, 110765
Identification and validation of Slit3 as a depression biomarker modulating dynorphinergic neurons in the hypothalamic paraventricular nucleus